Trial Profile

A Phase 1/2, Baseline-controlled, Non-randomized, Open-label, Single-ascending Dose Study of a Novel Adeno-associated Viral Vector (FLT190) in Patients With Fabry Disease

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jun 2024 According to Freeline Therapeutics media release, Freeline Therapeutics has changed its name to Spur Therapeutics.
02 Jun 2023 Status changed from active, no longer recruiting to discontinued as Freeline has decided to pause development of FLT190 in Fabry disease to focus its resources on advancing FLT201.
03 May 2023 This trial has been discontinued in Austria and France (End Date: 04 Apr 2023), according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com